Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

VANCOMYCIN HCL

All products: not a benefit

Other products in the same Health Canada class (A07AA) — coverage varies; not interchangeable

  • Rifaximin (Zaxine): limited Use 475

Jamp-Vancomycin · DIN 02407752 · 250mg · capsule

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Vancomycin Brand(s): Vancocin and other generics (Note that only specific DINs are reimbursed by the EAP) DOSAGE FORM/ STRENGTH: 125 mg capsules, 250 mg capsules (on case-by-case basis only) Effective September 30, 2019, Vancomycin oral tablets for the treatment of Uncomplicated Clostridium difficile infection may be accessed upon meeting Limited Use Criteria on the Ontario Drug Benefit Formulary. Vancomycin Injection to be used as an oral solution for Clostridium Difficile Infection may be accessed through the Telephone Request Service. Case-by-case consideration for requests not meeting the Limited Use criteria (e.g. higher doses, longer durations, tapering regimens exceeding the dosing limits under LU, complicated C.Difficile Infections) may be considered through external review. Please submit requests to EAP providing adequate and relevant clinical detail to support the request. 52 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 52, record 30, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)
1 brand, same coverage
Jamp-Vancomycin · DIN 02407752 Manufacturer: Jamp Pharma Corporation; listing date 2016-12-22 Health Canada: Marketed since 2021-06-17 · brand JAMP VANCOMYCIN · ATC A07AA09 VANCOMYCIN · form Capsule · route Oral · ingredients VANCOMYCIN (VANCOMYCIN HYDROCHLORIDE) 250 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Vancomycin: Formulary list price $10.3600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $10.3600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89246 · Verify on the e-Formulary ↗ (DIN 02407752)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02407752). DIN 02407752: Jamp-Vancomycin Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081228074; group id 54; item number 0111; lccId None; manufacturer id JPC Source form: Cap; strength: 250mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $10.3600; ministry $10.3600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02407752 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89246
Interchangeable products
Vancocin · DIN 00788716 · $10.3600
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02407752
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered

Matched class: 08:12:28 Other Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE Some products covered without a code (check the product listing): CEFADROXIL, CEFPROZIL, CEFTRIAXONE DISODIUM, CEFUROXIME AXETIL, CEPHALEXIN MONOHYDRATE, CLINDAMYCIN HCL, CLINDAMYCIN PHOSPHATE, TOBRAMYCIN, TOBRAMYCIN SULFATE 08:12:28 Other Antibiotics

RIFAXIMIN

· 1 products · Limited Use, codes 475 · strengths: 550mg · Tab

CEFADROXIL

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 500mg · Cap

CEFIXIME

· 4 products · General benefit · strengths: 20mg/mL, 400mg · Oral Susp, Tab

CEFPROZIL

· 17 products · General benefit (11), Listed, not a benefit (6) · strengths: 125mg/5mL, 250mg/5mL, 250mg, 500mg · Oral Susp-100mL Pk, Oral Susp-75mL Pk, Tab

CEFTRIAXONE DISODIUM

· 16 products · Listed, not a benefit (3), General benefit (10), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 0.25g/Vial, 1g/Vial, 2g/Vial, 10g/Vial · Inj Pd-Vial Pk

CEFUROXIME AXETIL

· 9 products · General benefit (7), Listed, not a benefit (2) · strengths: 125mg/5mL, 250mg, 500mg · Susp, Tab

CEPHALEXIN MONOHYDRATE

· 29 products · Listed, not a benefit (6), General benefit (23) · strengths: 250mg, 500mg, 25mg/mL, 50mg/mL · Cap, Pd for Oral Susp, Tab

CLINDAMYCIN HCL

· 20 products · Listed, not a benefit (2), General benefit (18) · strengths: 150mg, 300mg · Cap

CLINDAMYCIN PALMITATE

· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp

CLINDAMYCIN PHOSPHATE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 300mg/2mL · Inj Sol-2mL Pk

TOBRAMYCIN

· 3 products · Limited Use, codes 472 (1), General benefit (2) · strengths: 28mg, 300mg/5mL · Inh Pd-Cap, Inh Sol-5mL Pk

TOBRAMYCIN SULFATE

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 80mg/2mL · Inj Sol-2mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:28 and 4 more
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS VANCOCIN® (vancomycin hydrochloride capsules) is indicated for: • The treatment of infections caused by susceptible strains of the designated microorganisms in the following diseases and specific conditions: o staphylococcal enterocolitis, and o antibiotic associated pseudomembranous colitis produced by Clostridium difficile Parenteral administration of vancomycin is not effective for the indicated conditions; therefore VANCOCIN® must be given orally. VANCOCIN® is not effective by the oral route for the treatment of other types of infection. 1.1 Pediatrics Pediatrics (premature neonates and young infants): Evidence from clinical studies and experience suggests that use in premature neonates and young infants are associated with differences in safety and a brief discussion can be found in the Warnings and Precautions section. To reduce the development of drug-resistant bacteria and maintain the effectiveness of VANCOCIN® and other antibacterial drugs, VANCOCIN® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are availab… https://pdf.hres.ca/dpd_pm/00074630.PDF PM date: December 31, 1989 Source product: VANCOCIN; DIN 00788716; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Prepare an Exceptional Access request

SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE

Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.

EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026

EAP fax: In Ontario: 1-866-811-9908 or 416-327-7526 (Toronto area). Outside Ontario: 1-833-905-4260. Source; updated September 15, 2026

Posted turnaround and Telephone Request Service scope
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Source; updated September 15, 2026

Vancomycin (Vancocin and other generics (Note that only specific DINs are reimbursed)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Prepare answers: See the ministry wording below; no separate indication heading is held.

Ministry criteria corpus 2025-01-01; page 52

Vancomycin Brand(s): Vancocin and other generics (Note that only specific DINs are reimbursed by the EAP) DOSAGE FORM/ STRENGTH: 125 mg capsules, 250 mg capsules (on case-by-case basis only)
Effective September 30, 2019, Vancomycin oral tablets for the treatment of Uncomplicated Clostridium difficile infection may be accessed upon meeting Limited Use Criteria on the Ontario Drug Benefit Formulary.
Vancomycin Injection to be used as an oral solution for Clostridium Difficile Infection may be accessed through the Telephone Request Service.
Case-by-case consideration for requests not meeting the Limited Use criteria (e.g. higher doses, longer durations, tapering regimens exceeding the dosing limits under LU, complicated C.Difficile Infections) may be considered through external review. Please submit requests to EAP providing adequate and relevant clinical detail to support the request.
52

Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.